Polyclonal Antibody to 17-Beta-Hydroxysteroid Dehydrogenase Type 12 (HSD17b12)
Code | Size | Price |
---|
PAF182Ra01-20ul | 20ul | £92.00 |
Quantity:
PAF182Ra01-100ul | 100ul | £173.00 |
Quantity:
PAF182Ra01-200ul | 200ul | £234.00 |
Quantity:
PAF182Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
KAR; SDR12C1; Estradiol 17-beta-dehydrogenase 12; 3-Ketoacyl-CoA Reductase; Short Chain Dehydrogenase/Reductase Family 12C,Member 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
17-Beta-Hydroxysteroid Dehydrogenase Type 12
Reactivity:
Hu;Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blottin:g: 0.5-3ug/mL;
Immunohistochemistry: 5-30ug/mL;
Immunocytochemistry: 5-30ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-30ug/mL;
Immunocytochemistry: 5-30ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant 17-Beta-Hydroxysteroid Dehydrogenase Type 12 (HSD17b12) | RPF182Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||